Limit search to available items
Book Cover

Title Hormone therapy and castration resistance of prostate cancer / Yoichi Arai, Osamu Ogawa, editors
Published Singapore : Springer, 2018
Online access available from:
Springer eBooks    View Resource Record  


Description 1 online resource (viii, 433 pages) : illustrations (some color)
Contents Intro; Contents; 1: Introduction; 2: Recent Trends in Hormone Therapy for Prostate Cancer in Japan; 2.1 Introduction; 2.2 Source of Data; 2.3 Trend in Hormonal Therapy as Main Treatment; 2.3.1 Initial Treatment Patterns in Japan; 2.3.2 Treatment Pattern Difference Between Japan and the USA; 2.3.3 Types of Hormonal Therapy in Japan; 2.3.4 Types of Castration; 2.3.5 Types of Antiandrogen; Reference; 3: Risk Assessment Among Patients Receiving Primary ADT for Prostate Cancer; 3.1 TNM Classification; 3.2 J-CAPRA Score; 3.3 Risk Assessment in the Next Generation; References
4: Patient-Derived Xenografts for Research on Hormonal Therapy of Prostate Cancer4.1 Introduction; 4.2 Establishment of Prostate Cancer Patient-Derived Xenograft Models; 4.3 Basic and Clinical Application of PDX Models for Understanding Resistance to Hormonal Therapy; 4.4 Future Perspectives; References; 5: Impact of GnRH Antagonist and LHRH Agonist on the Gonadal Axis; 5.1 Impact of GnRH Antagonist and LHRH Agonist on the Gonadal Axis; 5.1.1 First Impact: Discovery of LHRH Agonist; 5.1.2 Second Impact: New Hope, GnRH Antagonist
5.1.3 Relationship Between LHRH Agonist and Adrenal Androgen5.1.4 The Effect of Antagonist on Adrenal Androgen; References; 6: Controversies on Combined Androgen Blockade for Prostate Cancer; References; 7: Adrenal Androgen in Prostate Cancer; 7.1 Introduction; 7.2 Evaluation of Prostate Androgen Concentration by Highly Sensitive Quantitative Analysis; 7.3 Hormone Metabolism in the Prostate; 7.4 Role of Adrenal-Derived Androgens in PCa; References; 8: Intermittent ADT for Prostate Cancer; 8.1 Introduction; 8.2 Concept of Intermittent ADT; 8.3 Intermittent ADT in Animal Models
8.4 Clinical Experiences of Intermittent ADT8.5 Randomized Controlled Trials and Meta-analyses/Systematic Reviews Comparing Intermittent Versus Continuous ADT; 8.6 Clinical Guidelines Concerning Intermittent ADT; 8.7 Methods of Intermittent ADT; 8.8 Advantages and Disadvantages of Intermittent ADT; 8.9 Future Directions for Intermittent ADT; References; 9: Prognostic Significance of Monitoring Serum Testosterone in Primary ADT for Prostate Cancer; 9.1 Introduction; 9.2 The Significance of Lower Testosterone Level Below 50 ng/dL
9.3 The Difference in Clinical Outcome Between GnRH Antagonist and LHRH Agonist9.4 Intratumoral Androgen Synthesis; 9.5 Significance of TST Suppression at Early Stage of Prostate Cancer; 9.6 Future Directions; References; 10: Ethnic Variation in Clinical Outcomes of Hormone Therapy for Prostate Cancer; 10.1 Introduction; 10.2 Impact of Ethnicity on the Survival of Men with Prostate Cancer in the United States; 10.3 Comparison of Clinical Outcome of Prostate Cancer Among Various Ethnics in Hawaii; 10.3.1 Comparison of Clinical Outcome Between Caucasians and Japanese
Summary This comprehensive reference expounds the current state of hormone therapy and castration resistance of prostate cancer (PCa). Previously, the incidence of PCa in Asian countries was relatively low, but it has been increasing dramatically in recent years. Although most of the new cases are diagnosed in early stages, a significant proportion of patients receive hormone therapy for metastatic disease or for relapse after local treatment. Thus the situation has gradually changed toward earlier and longer use of hormone therapy. The malignancy finally forms castration-resistant prostate cancer (CRPC) despite the lack of testicular androgen. With advances in understanding of the molecular basis of hormone dependence and CRPC, many new androgen receptor-targeted agents have emerged. During the last decade, much evidence on hormone therapy has been accumulated in Japan. Interestingly, some of these findings are different from those reported from Western countries, suggesting ethnic variation in the outcome of hormone therapy. In the chapters of this book, expert authors provide exhaustive interpretations of the evidence recently reported from Japan and provide important Asian perspectives on hormone therapy for PCa. This work benefits not only Asian urologists but also their Western counterparts and all physicians and medical personnel who are involved in the treatment of PCa
Notes Online resource; title from PDF title page (SpringerLink, viewed May 14, 2018)
Subject Prostate -- Cancer -- Hormone therapy.
Form Electronic book
Author Arai, Yƍichi, editor
Ogawa, Osamu, editor
ISBN 9789811070136 (electronic bk.)
981107013X (electronic bk.)